Nicox receives Zerviate milestone payment from Eyevance

The completion of regulatory and manufacturing activities for the launch of Zerviate in the U.S. has triggered a $3 million milestone payment from Eyevance Pharmaceuticals to Nicox, according to a press release.

The licensing agreement between the two companies, signed in September 2017, stipulated that Nicox would provide pre-launch manufacturing support and complete scale-up activities for manufacture of Zerviate (cetirizine ophthalmic solution 0.24%).

Nicox is eligible for an additional $37.5 million in milestone payments depending on sales target achievements, as well as tiered royalties of future sales.

Zerviate is a topical ocular antihistamine intended for treatment of itching associated with allergic conjunctivitis. The launch is projected in the first half of 2020.

The completion of regulatory and manufacturing activities for the launch of Zerviate in the U.S. has triggered a $3 million milestone payment from Eyevance Pharmaceuticals to Nicox, according to a press release.

The licensing agreement between the two companies, signed in September 2017, stipulated that Nicox would provide pre-launch manufacturing support and complete scale-up activities for manufacture of Zerviate (cetirizine ophthalmic solution 0.24%).

Nicox is eligible for an additional $37.5 million in milestone payments depending on sales target achievements, as well as tiered royalties of future sales.

Zerviate is a topical ocular antihistamine intended for treatment of itching associated with allergic conjunctivitis. The launch is projected in the first half of 2020.